NCT07045558View on ClinicalTrials.gov

HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC

Not yet recruitingOBSERVATIONAL
Enrollment

28

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2028

Conditions
Unresectable Hepatocellular Carcinoma
Trial Locations (1)

Unknown

Renji Hospital affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT07045558 - HAIC + Atezolizumab Plus Bevacizumab in Unresectable HCC | Biotech Hunter | Biotech Hunter